Canaccord Initiates Illumina Coverage with Buy Rating | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity today started coverage of Illumina with a Buy rating and a $275 price target on the firm's stock. 

Noting the flush next-generation sequencing market and the large shadow cast by Illumina in the space, Canaccord analyst Mark Massaro called Illumina "a must-own stock for large-cap growth … given the company's dominant leadership position, innovation, and pipeline in the dynamic next-generation sequencing market opportunity we peg at close to $50 billion by the end of the decade." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.